Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch

US FDA Cleared KRAS G12C Inhibitor For Second-Line NSCLC

 
• By Mandy Jackson
Red paper lungs on wood background
Lumakras is approved for second line or later KRAS G12C-mutated non-small cell lung cancer • Source: Alamy

More from New Products

More from Scrip